Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

doi:10.2165/00023210-200923030-00001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

CNS drugs - 1 Jan 2009

Kirchheiner Julia, Rodriguez-Antona Cristina

Abstract excerpt

The specific reaction toward a given drug varies a lot between individuals and, for many drugs, pharmacogenetic polymorphisms are known to affect biotransformation and clinical outcome. Estimation of the individual's drug-metabolizing capacity can be undertaken by genotyping drug-metabolizing enzymes involved in the respective drug metabolism. Consequences that arise from genotyping may be the adjustment of dose...

Topics

Adult
Antipsychotic Agents
Atomoxetine Hydrochloride
Attention Deficit Disorder with Hyperactivity
Child
Cytochrome P-450 CYP2D6
Genotype
Humans
Mental Disorders
Pharmacogenetics
Polymorphism, Genetic
Propylamines
Psychotropic Drugs
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 19320528
DOI: 10.2165/00023210-200923030-00001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics